Literature DB >> 23616111

Emerging new therapeutic alternatives for the management of cancer cachexia: recent insights.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23616111     DOI： 10.1007/s00520-013-1820-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  7 in total

1.  Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia.

Authors:  Katsutoshi Ando; Fumiyuki Takahashi; Shinji Motojima; Kei Nakashima; Norihiro Kaneko; Kazuei Hoshi; Kazuhisa Takahashi
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

2.  mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass.

Authors:  Steven D Kunkel; Manish Suneja; Scott M Ebert; Kale S Bongers; Daniel K Fox; Sharon E Malmberg; Fariborz Alipour; Richard K Shields; Christopher M Adams
Journal:  Cell Metab       Date:  2011-06-08       Impact factor: 27.287

3.  Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

Authors:  Michelle L Asp; Min Tian; Kara L Kliewer; Martha A Belury
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

4.  Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.

Authors:  José M Garcia; John Friend; Suzan Allen
Journal:  Support Care Cancer       Date:  2012-06-16       Impact factor: 3.603

5.  The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.

Authors:  R Dallmann; P Weyermann; C Anklin; M Boroff; K Bray-French; B Cardel; I Courdier-Fruh; H Deppe; J Dubach-Powell; M Erb; R H Haefeli; M Henneböhle; H Herzner; M Hufschmid; D L Marks; S Nordhoff; M Papp; C Rummey; G Santos; F Schärer; H Siendt; M Soeberdt; L T Sumanovski; M Terinek; C Mondadori; N Güven; A Feurer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-08-28       Impact factor: 12.910

6.  The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.

Authors:  Andrew J Stewart Coats; Venkatesan Srinivasan; Jayaraman Surendran; Haritha Chiramana; Shankar R K G Vangipuram; Nirajkumar N Bhatt; Minish Jain; Sandip Shah; Irfhan A B H Ali; Ho G Fuang; Mohammed Z M Hassan; John Beadle; Julia Tilson; Bridget-Anne Kirwan; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-10-16       Impact factor: 12.910

7.  Theophylline is able to partially revert cachexia in tumour-bearing rats.

Authors:  Mireia Olivan; Jochen Springer; Sílvia Busquets; Anika Tschirner; Maite Figueras; Miriam Toledo; Cibely Fontes-Oliveira; Maria Inés Genovese; Paula Ventura da Silva; Angelica Sette; Francisco J López-Soriano; Stefan Anker; Josep M Argilés
Journal:  Nutr Metab (Lond)       Date:  2012-08-21       Impact factor: 4.169
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.